However, due to technological limitations and YAP/TAZ’s inherent ability to regulate multiple stem cell activities and tissue regeneration, direct targeting of YAP/TAZ for tumor treatment is facing major strategic challenges. This evidence concerns the gene YAP1 and neoplasm.